U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations)
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations) July 2021

Final
Docket Number:
FDA-2020-D-1456
Issued by:
Guidance Issuing Office
Center for Food Safety and Applied Nutrition

The purpose of this document is to highlight the chemistry issues that FDA recommends that a manufacturer of recycled plastic consider during the manufacturer's evaluation of a recycling process for producing material suitable for food-contact applications.  This document supersedes the December 1992 “Points to Consider for the Use of Recycled Plastics in Food Packaging:  Chemistry Considerations” (1992 “Points to Consider”).  The possibility that chemical contaminants in plastic materials intended for recycling may remain in the recycled material and could migrate into the food the material contacts is one of the major considerations for the safe use of recycled plastics for food-contact applications.  Other aspects of plastics recycling, such as microbial contamination and structural integrity of the recycled plastic, are also important, but are not discussed in this document.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

Download the Guidance


This guidance was revised to include Paperwork Reduction Act information, containing non-substantive formatting or editorial revisions to the guidance, which was originally issued in August 2006. Revisions are noted by date at the end of the guidance.


Related Information


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-1456.

 
Back to Top